1 / 16

Laurent Bonello, MD Unité de cardiologie interventionnelle Pôle de cardiologie

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 2* loss-of function polymorphism. Laurent Bonello, MD Unité de cardiologie interventionnelle Pôle de cardiologie Hôpital universitaire nord de Marseille FRANCE.

josephine-taylor
Télécharger la présentation

Laurent Bonello, MD Unité de cardiologie interventionnelle Pôle de cardiologie

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 2* loss-of function polymorphism. Laurent Bonello, MD Unité de cardiologie interventionnelle Pôle de cardiologie Hôpital universitaire nord de Marseille FRANCE

  2. Potential conflicts of interest Speaker’s name: BONELLO Laurent  I have the following potential conflicts of interest to report:  Research contracts  Consulting  Employment in industry  Stockholder of a healthcare company  Owner of a healthcare company  Other(s) xI do not have any potential conflict of interest

  3. CLOPIDOGREL • LIMITS: • Slow onset of action • Large and unpredictable inter-individual variability Bonello et al. Heart 2009

  4. Relationship between Post-Treatment PR and post-PCI outcome. Bonello et al. JACC 2010 In press.

  5. VASP studies: PR could be used as a surrogate endpoint PR monitoring enables optimal PR inhibition to be reached which translates into a reduction in thrombotic events post-PCI without increased bleeding. Bonello et al. AJC 2009.

  6. Clopidogrel metabolism Simon T. et al. N EJM 2008; Megat et al. NEJM 2008.

  7. 2C19 2* loss-of function polymorphism is associated with a worse outcome post-PCI in clopidogrel-treated patients CV Death / MI / Stroke 12-15 months Megat et al. NEJM 2008.

  8. Investigate the biological impact of tailored clopidogrel LD according to PR monitoring in carriers of the CYP 2C19 2* loss-of function polymorphism undergoing PCI. AIM

  9. METHOD prospective multicenter study dose adjustment is performed by using up-to three additional LD of clopidogrel until a VASP <50% was obtained. HTPR: VASP ≥50% .Primary end-point: PR <50% in « HTPR » patients .Secondary: In-hospital bleeding and MACE

  10. 134 patients (35.3%) carried at least one loss of function 2C19 2* alleles 11 homozygotes (2.7%) and 123 heterozygotes (32.6%). VASP index was significantly higher than that of WT homozygotes (61.7 ±18.4 vs 49.2 ±24.2%; p<0.001). 104/134 (77.6%) were considered to have HTPR. After a 2nd LD, the VASP index was significantly decreased in these patients (69.7 ±10.1 vs 50.6 ±17.6 %; p <0.0001). RESULTS Biological impact of a 2nd clopidogrel LD in carriers of CYP 2C19 2* with HTPR.

  11. Dose-adjustment in Heterozygotes • 123 Heterozygotes; 88 with HTPR • Dose adjustement was successful in 77/88 (88%)

  12. Dose-adjustment in Homozygotes • 11 homozygotes for the 2C19 2* alleles • 6 had HTPR and 5 / 6 reached a PR<50% after dose adjustement

  13. Final VASP in 2C19 2* carriers • Among 2C19 2* carriers, factors associated with failed dose adjustment in multivariate analysis: • BMI OR : 20.9 (95% CI: 3.9-11.8; p<0.00.1) • gender OR : 6.8 (HR 1.2- 40.4; p=0.03). • Finally, dose-adjustment was efficient in 88% of 2C19 2* carriers with HTPR to reach a <50% using up-to three additional 600 mg LD of clopidogrel.

  14. In-hospital outcomes 2 MACE : 1 stroke and 1 SAT (Htz with FDA). 4 minor TIMI bleedings: Hmz WT.

  15. Increased and tailored loading dose of clopidogrel overcome HTPR in carriers of the loss-of function 2C19 2* polymorphism. Since studies have demonstrated the clinical benefit of dose-adjustement in patients with HTPR undergoing PCI, this therapeutic strategy may improve the prognosis of carriers of this loss-of function polymorphism. CONCLUSION

  16. Armero Sébastien, Ait Mokhtar Omar, Aldebert Philippe, Bartho Marie-Noelle, Franck Paganelli Mancini Julien, Saut Noémie, Bonello Nathalie Barragan Paul Arques Stéphane Giacomoni Marie-Paule, Dignat-George Françoise, Camoin-Jau Laurence Marie-Christine Alessi, Karine Berthaux. Aknowledgements

More Related